Why Moxifloxacin’s Approval for Plague Is So Disturbing

PLEASE SHARE YOUR OPINION AND VOTE BELOW On May 8th, 2015 moxifloxacin/Avelox was approved for treatment of inhalational plague.[1]   We learn that the approval followed the ‘animal rule’ process, and that treatment with moxifloxacin was 100% effective in the African Green Monkey (AGM) model of lung infection.  By contrast, 0% of Continue reading Why Moxifloxacin’s Approval for Plague Is So Disturbing

Cresemba / Isavuconazole:  Not Just Another Azole

It is amazing how modifications to the azole structure have produced ever more potent, ever more useful antifungals.  Ketoconazole had limited usability because of its many side effects related to off-target sterol synthesis inhibition, solubility (or lack thereof) and erratic absorption.  Solublity was also an issue for itraconazole and posaconazole.  Continue reading Cresemba / Isavuconazole:  Not Just Another Azole

Aerosolized Antibiotics & Selling Nebulizers

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent antibiotics. The inhalational route to administer antibiotics is clearly attractive.  Continue reading Aerosolized Antibiotics & Selling Nebulizers